Welcome to PrecisionPhage

PrecisionPhage Ltd. is a Finland-based biotech company specializing in bacteriophage technologies.

We provide services ranging from bioinformatic analyses to bacteriophage licensing and various laboratory services.


What are bacteriophages?

Bacteriophages (phages) are viruses that attack bacteria. Phages can be used as an alternative to antibiotics to treat infections. The benefits of phage therapy over antibiotics include:

  • Precision. Unlike antibiotics, phages generally only attack their target bacteria
  • Diversity. There is likely a phage for every bacterium out there, even for the antibiotic-resistant ones
  • Flexibility and evolvability Phages can be combined to a "phage cocktail" against which bacterial resistance is less likely to develop. Phages can also be evolved to target a specific bacterial strain.

Products and services

We offer computational and laboratory-based phage services


Our online phage genome management and analysis toolkit Phagenomics combines complex bioinformatic analyses into a streamlined package:

  • Genome assembly. Submit your raw sequencing reads to our automated assembly pipeline. After an hour, you'll have a quality-controlled phage genome assembly.

  • Genome analysis. Analyse your newly assembled phage genome for its suitability for phage therapy. Alternatively, submit your own assembly.

  • Comparative genomics True analytical power comes from comparison. Compare phage attributes and create heatmaps, alignments and other comparative genomic analyses in the browser.

Phagenomics will be released in 2023

Phage collection

We have obtained a substantial collection of bacteriophages over the last decade. The main targets of the collection are the following (antibiotic-resistant) pathogens:

  • Escherichia coli

  • Klebsiella pneumoniae

  • Pseudomonas aeruginosa

  • Acinetobacter baumannii

We also have a collection of other phages, such as

  • individual phages against various other clinically relevant bacterial species

  • specialized phages such as those that are specific to conjugative resistance plasmids.

All our phages are sequenced, their genomes analyzed, cross-infectivities tested and various relevant characteristics determined.

At the moment, we do not offer phage-therapy services.

Phage collection services

  • We offer screening against the PrecisionPhage collection for strains of Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii.
    The identified infectious phages may be utilized in research or developmental purposes under licensing agreements formed between PrecisionPhage and the licencor.
    We offer supplementing information on the phages such as phage genomic sequences, genetic comparison between all identified phages in the collection and initial phage titers to facilitate the selection of most suitable phages for your specific purpose.

  • We offer exclusive and non-exclusive licenses for the utilization of PrecisionPhage phages.
    Exclusive licensing provides the licensor an exclusive right to utilize the phage for the duration of the licensing period.
    Non-exclusive licenses provides the rights to utilize the phages, but with the possibility that other licensors may be utilizing non-exclusively the same phages. Exclusively licensed phages are not available for non-exclusive licensing, and vice versa. Details of all contracts are negotatied on case by case basis.

Phage laboratory services

PrecisionPhage management and employees have extensive backgrounds in bacteriophage research. We serve our customers by offering laboratory services in key developmental steps in bacteriophage-based solutions, including but not limited to:

  • On-demand phage isolation
  • Small-scale phage production
  • Sequencing
  • Genomic analyses

On-demand phage isolation

We can isolate and characterize bacteriophages against specific bacterial strains. The isolated phages can be licensed or purchased based on the established contracts. At the moment this service is limited to bacterial species and strains of biosafety-level (BSL) 2 (or below) bacteria. For a substantial number of BSL3 strains, we offer options for developmental cooperation.

Invest in PrecisionPhage

We warmly welcome potential investors. To learn more about investment opportunities, please contact us.


Matti Jalasvuori, PhD, Dos.

Chief Executive Officer (CEO)

Liisa Chisty, PhD

Chief Business Officer (CBO)

Ville Hoikkala, PhD

Chief Bioinformatician

Saija Kiljunen, PhD, Dos.

Scientific Officer


We're happy to talk. Get in touch!


Survontie 9, 40500 Jyväskylä, Finland


+358 50413 5092